Noteworthy

Feb 01, 2012
Pharmaceutical Executive
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
Feb 01, 2012
Pharmaceutical Executive
Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".
Feb 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
State tech transfer laws giving universities automatic ownership of employees' inventions represent a threat to pharma partnerships—but the Supreme Court is poised to intervene in the industry's favor.
Feb 01, 2012
Pharmaceutical Executive
For a rendering to be effective, the right balance must be struck between captivating art and accurate science.
Jan 01, 2012
From Pharmaceutical Technology Europe
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.
Jan 01, 2012
Pharmaceutical Executive
Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Jan 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Mason Tenaglia offers empirical defense of coupons and copay offset programs.
Jan 01, 2012
Pharmaceutical Executive
A selection of the recent breakthrough technologies showcased at the Cleveland Clinic's Medical Innovations Summit.
native1_300x100
lorem ipsum